@dhovekamp42 $KTOV also has a head and neck cancer program in preclinical phase: NT-219.
And their CM-24 program still is in combination with $MRK their pembrolizumab MK-3475
https://t.co/cMY3n2rIXH
The site says terminated, but they continue to develop the drug. A PR is expected in june.